Phase Ii study of lonidamine in patients with small cell carcinoma of the lung

Murray, N.; Shah, A.; Band, P.

Cancer Treatment Reports 71(12): 1283-1284

1987


ISSN/ISBN: 0361-5960
PMID: 2825992
Document Number: 287914
Lonidamine, a substituted indazole carboxylic acid that inhibits cellular respiration, was given in an escalating oral schedule to 20 evaluable patients with measurable extensive small cell carcinoma of the lung. Two partial responses occurred. Reversible acceptable toxicity included myalgia, nausea, hyperesthesia, photophobia, somnolence, and testicular pain. The drug was not myelosuppressive. Lonidamine has modest activity in small cell lung cancer and further studies are warranted.

Document emailed within 1 workday
Secure & encrypted payments